/** blogpostTitle: Dhanuka Agritech Q4 FY26: Profitability Improves, FY27 Guidance Turns Cautious blogpostSlug: dhanuka-q4fy26 blogpostCoverImageUrl: null blogpostCoverImageDescription: Ultra realistic corporate financial scene inside a modern Indian boardroom, with a clean dashboard-style screen showing three charts: quarterly revenue rising from about 442 to 483, EBITDA margin near mid-20s, and a pie chart of Q4 revenue mix split into four segments with the largest slice around 41%. On a side panel, a second pie chart shows geography split with North, South, East, West. Neutral lighting, no logos or text labels. blogpostShortTitle: Dhanuka Q4 FY26 results and guidance */

Dhanuka Agritech Q4 FY26: Profitability Improves, FY27 Guidance Turns Cautious

Dhanuka Agritech ended Q4 FY26 with a better quarter on the surface, but the management commentary made it clear that not all of the improvement is structural. Revenue from operations in Q4 FY26 rose to INR 483.34 crore from INR 442.02 crore in Q4 FY25. EBITDA increased to INR 124.89 crore from INR 109.75 crore, and PAT rose sharply to INR 97.77 crore from INR 75.50 crore.

The Q4 margin print was strong, with EBITDA margin at 25.84% and PAT margin at 20.23%. However, management attributed a meaningful part of the Q4 profitability strength to a GST refund, particularly related to the Udhampur unit. This matters because the same management team guided for an approximately 100 bps decline in EBITDA margin in FY27.

For the full year, the picture was flatter. FY26 revenue from operations was INR 2,019.79 crore, slightly lower than INR 2,035.15 crore in FY25. FY26 EBITDA was INR 403.48 crore compared with INR 416.61 crore, while FY26 PAT was INR 287.23 crore versus INR 296.96 crore.

What moved in Q4: Segment and region mix stayed diversified

Dhanuka’s Q4 revenue mix by product segment remained balanced across categories. Insecticides contributed 41% of Q4 revenue, herbicides 31%, fungicides 14%, and others 14%. The management also shared region-wise contribution: North 32%, South 33%, West 23%, and East 12%.

The company positioned this diversification as a resilience factor in a year where demand patterns were affected by uneven climate and local crop economics.

FY27 guidance: Growth to return, margins to normalize

In the investor presentation, Dhanuka guided for lower double digit growth in revenue from operations in FY27. At the same time, it guided for an EBITDA margin decline of about 100 bps.

In the conference call, management linked the margin decline largely to two factors: the GST refund benefit that lifted FY26 profitability and a reduction in net economic benefit. The GST refund for FY26 was stated at around INR 29 crore, with around INR 14.5 crore recognized in Q4.

Input costs were another live topic. Management stated that post-war volatility in March and April led to price increases, which later stabilized. The company explained that, as a basket, imported raw materials were impacted by roughly 5% to 6% due to rupee depreciation, while some indigenous generics saw sharper inflation. On an overall basket level, management pegged raw material inflation at roughly 3% to 5%.

On pricing, management said passing on cost increases to customers is not immediate. Some part of price hikes has already been taken in Q1, and additional hikes may be required in Q2. The company expects pass-through to happen over time, rather than instantly.

Portfolio actions: Bayer acquisitions, biostimulants reboot, and overseas enablement

A key medium-term lever discussed in the concall was the integration of two acquired Bayer products: Triadimenol and Iprovalicarb. Management clarified that Bayer largely continued commercialization in most markets during FY26. The more immediate work for Dhanuka is operational: appointing distributors, managing supply chains, and improving cost efficiency through localization.

The company stated it has initiated formulation of both Melody variants in India. It expects Triadimenol formulation to shift to India within FY27. For Iprovalicarb, management indicated technical production could begin by the end of FY27. It also clarified that only one molecule’s active ingredient will be manufactured in India, while the other active ingredient will be procured from outside. Both products’ formulations are expected to shift to India because that improves supply chain efficiency and reduces costs.

Biostimulants and biologicals were another focus area. Management said this category’s revenue fell to about INR 70 crore in FY26 from about INR 110 crore in FY25 due to biostimulant regulations. For FY27, management expects revenue of more than INR 130 crore, supported by planned product launches. It stated that one molecule was launched in FY26 and three products will be launched in June.

On the international business, management was candid about challenges. While it said registration is not the biggest issue, it highlighted difficulties at the distributor level. Distributors in certain markets either cannot commit volumes or seek to sell at lower prices than what the company finds workable.

A related corporate action was announced through the board outcome: Dhanuka approved setting up wholly owned subsidiaries outside India in a European country and Brazil. The stated purpose is to support growth outside India, primarily to transfer registrations of brands acquired from Bayer and register other products in the company’s name. The initial investment limit mentioned was INR 1 crore per entity, subject to increase based on business needs and board approval.

Capital allocation: Dividend, buyback, and employee incentive plans

The board recommended a final dividend of 100%, which equals INR 2 per equity share of face value INR 2. It also approved a buyback of up to 5,00,000 shares (about 1.11% of paid-up equity capital) for an aggregate amount not exceeding INR 70 crore at a maximum buyback price of INR 1,400 per share.

In addition, the board approved an Employee Stock Option Plan 2026 and a Stock Appreciation Rights Plan 2026, both subject to shareholder approval at the upcoming AGM. The ESOP pool is up to 50,000 options (about 0.11% of equity share capital). The SAR plan is up to 1,25,000 SARs (corresponding to about 0.28% of equity share capital). The company stated a minimum vesting period of one year and an exercise period that can extend up to eight years from the grant date.

Takeaways

Dhanuka’s Q4 FY26 delivered better growth and profitability, but management was explicit that a portion of the margin strength came from GST refunds, and that FY27 margins may normalize as that benefit disappears. The FY27 growth guidance of lower double digits indicates confidence in demand recovery, but also acknowledges input cost and channel dynamics.

The near-term watchlist is clear from management commentary. First, the pace and sustainability of price pass-through amid raw material inflation. Second, the rebound in biostimulants and biologicals toward the company’s stated FY27 revenue expectation of more than INR 130 crore. Third, execution on the Bayer-acquired product integration and localization plan, including the shift of formulations to India and planned technical production milestones.

The shareholder payout mix of dividend and buyback, along with incremental steps toward overseas enablement via planned subsidiaries, rounds out a year that was steady on revenue but eventful in strategy and capital allocation.